Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2008 (2008), Article ID 564969, 9 pages
http://dx.doi.org/10.1155/2008/564969
Research Article

Preparation and Characterization of a Novel Chimeric Protein VEGI-CTT in Escherichia coli

Department of Ophthalmology, Second Affiliated Hospital, Second Military Medical University, Shanghai 200433, China

Received 13 December 2007; Revised 5 May 2008; Accepted 21 June 2008

Academic Editor: Shahid Jameel

Copyright © 2008 Jiping Cai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Ferrara, K. J. Hillan, H.-P. Gerber, and W. Novotny, “Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer,” Nature Reviews Drug Discovery, vol. 3, no. 5, pp. 391–400, 2004. View at Publisher · View at Google Scholar · View at PubMed
  2. D. M. McDonald, B. A. Teicher, W. Stetler-Stevenson et al., “Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring,” Journal of Immunotherapy, vol. 27, no. 2, pp. 161–175, 2004. View at Google Scholar
  3. J. Folkman, “Endogenous angiogenesis inhibitors,” APMIS, vol. 112, no. 7-8, pp. 496–507, 2004. View at Publisher · View at Google Scholar · View at PubMed
  4. Y. Zhai, J. Yu, L. Iruela-Arispe et al., “Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily,” International Journal of Cancer, vol. 82, no. 1, pp. 131–136, 1999. View at Publisher · View at Google Scholar
  5. Y. Zhai, J. Ni, G. Jiang et al., “VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo,” The FASEB Journal, vol. 13, no. 1, pp. 181–189, 1999. View at Google Scholar
  6. T.-L. Yue, J. Ni, A. M. Romanic et al., “TL1, a novel tumor necrosis factor-like cytokine, induces apoptosis in endothelial cells: involvement of activation of stress protein kinases (stress-activated protein kinase and p38 mitogen-activated protein kinase) and caspase-3-like protease,” The Journal of Biological Chemistry, vol. 274, no. 3, pp. 1479–1486, 1999. View at Publisher · View at Google Scholar
  7. L.-J. Chew, H. Pan, J. Yu et al., “A novel secreted splice variant of vascular endothelial cell growth inhibitor,” The FASEB Journal, vol. 16, no. 7, pp. 742–744, 2002. View at Publisher · View at Google Scholar · View at PubMed
  8. J. Yu, S. Tian, L. Metheny-Barlow et al., “Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor,” Circulation Research, vol. 89, no. 12, pp. 1161–1167, 2001. View at Publisher · View at Google Scholar
  9. B. B. Aggarwal and K. Natarajan, “Tumor necrosis factors: developments during the last decade,” European Cytokine Network, vol. 7, no. 2, pp. 93–124, 1996. View at Google Scholar
  10. T.-S. Migone, J. Zhang, X. Luo et al., “TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator,” Immunity, vol. 16, no. 3, pp. 479–492, 2002. View at Publisher · View at Google Scholar
  11. L. A. Liotta, K. Tryggvason, S. Garbisa, I. Hart, C. M. Foltz, and S. Shafie, “Metastatic potential correlates with enzymatic degradation of basement membrane collagen,” Nature, vol. 284, no. 5751, pp. 67–68, 1980. View at Publisher · View at Google Scholar
  12. G. Karakiulakis, C. Papanikolaou, S. M. Jankovic et al., “Increased type IV collagen-degrading activity in metastases originating from primary tumors of the human colon,” Invasion & Metastasis, vol. 17, no. 3, pp. 158–168, 1997. View at Google Scholar
  13. E. Koivunen, W. Arap, H. Valtanen et al., “Tumor targeting with a selective gelatinase inhibitor,” Nature Biotechnology, vol. 17, no. 8, pp. 768–774, 1999. View at Publisher · View at Google Scholar · View at PubMed
  14. J. Folkman, “Angiogenic zip code,” Nature Biotechnology, vol. 17, no. 8, pp. 749–758, 1999. View at Publisher · View at Google Scholar · View at PubMed
  15. R. J. Kreitman, Q.-C. Wang, D. J. P. FitzGerald, and I. Pastan, “Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys,” International Journal of Cancer, vol. 81, no. 1, pp. 148–155, 1999. View at Publisher · View at Google Scholar
  16. M. S. O'Reilly, L. Holmgren, Y. Shing et al., “Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma,” Cell, vol. 79, no. 2, pp. 315–328, 1994. View at Publisher · View at Google Scholar
  17. M. S. O'Reilly, T. Boehm, Y. Shing et al., “Endostatin: an endogenous inhibitor of angiogenesis and tumor growth,” Cell, vol. 88, no. 2, pp. 277–285, 1997. View at Publisher · View at Google Scholar
  18. R. Ramchandran, M. Dhanabal, R. Volk et al., “Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin,” Biochemical and Biophysical Research Communications, vol. 255, no. 3, pp. 735–739, 1999. View at Publisher · View at Google Scholar · View at PubMed
  19. R. Xu, L. Xin, J.-M. Zhang, Z.-P. Li, and R.-B. Gan, “Restin expressed in vivo suppresses the growth of tumors in nude mice,” Acta Biochimica et Biophysica Sinica, vol. 34, no. 5, pp. 571–575, 2002. View at Google Scholar
  20. G. D. Kamphaus, P. C. Colorado, D. J. Panka et al., “Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth,” The Journal of Biological Chemistry, vol. 275, no. 2, pp. 1209–1215, 2000. View at Publisher · View at Google Scholar
  21. W. Hou, B. Yuan, T. Wang et al., “Construction of prokaryotic expression vector for human canstatin and its expression,” Journal of Zhengzhou University (Medical Science), vol. 39, pp. 51–54, 2004. View at Google Scholar
  22. Y. Maeshima, A. Sudhakar, J. C. Lively et al., “Tumstatin, an endothelial cell-specific inhibitor of protein synthesis,” Science, vol. 295, no. 5552, pp. 140–143, 2002. View at Publisher · View at Google Scholar · View at PubMed
  23. Y. Maeshima, P. C. Colorado, and R. Kalluri, “Two RGD-independent αvβ3 integrin binding sites on tumstatin regulate distinct anti-tumor properties,” The Journal of Biological Chemistry, vol. 275, no. 31, pp. 23745–23750, 2000. View at Publisher · View at Google Scholar · View at PubMed
  24. J.-Q. Guo, S.-Y. You, L. Li, Y.-Z. Zhang, J.-N. Huang, and C.-Y. Zhang, “Construction and high-level expression of a single-chain Fv antibody fragment specific for acidic isoferritin in Escherichia coli,” Journal of Biotechnology, vol. 102, no. 2, pp. 177–189, 2003. View at Publisher · View at Google Scholar
  25. M. H. Hefti, F. J. Milder, S. Boeren, J. Vervoort, and W. J. H. van Berkel, “A His-tag based immobilization method for the preparation and reconstitution of apoflavoproteins,” Biochimica et Biophysica Acta, vol. 1619, no. 2, pp. 139–143, 2003. View at Publisher · View at Google Scholar
  26. F. A. O. Marston, P. A. Lowe, M. T. Doel, J. M. Schoemaker, S. White, and S. Angal, “Purification of calf prochymosin (prorennin) synthesized in Escherichia coli,” Bio/Technology, vol. 2, no. 9, pp. 800–804, 1984. View at Publisher · View at Google Scholar
  27. M. E. Winkler, M. Blaber, G. L. Bennett, W. Holmes, and G. A. Vehar, “Purification and characterization of recombinant urokinase from Escherichia coli,” Bio/Technology, vol. 3, no. 11, pp. 990–1000, 1985. View at Publisher · View at Google Scholar
  28. R. Amons and P. I. Schrier, “Removal of sodium dodecyl sulfate from proteins and peptides by gel filtration,” Analytical Biochemistry, vol. 116, no. 2, pp. 439–443, 1981. View at Publisher · View at Google Scholar
  29. E. De Bernardez Clark, “Refolding of recombinant proteins,” Current Opinion in Biotechnology, vol. 9, no. 2, pp. 157–163, 1998. View at Publisher · View at Google Scholar